Most Recent Articles by James G. Dickinson
Expect major changes in the way the FDA does business with drug companies after the Trump administration takes over in January.
That change is coming about in the wake of a string of First Amendment-based losses for the FDA in federal courts around the country.
Would you expect that patient power exerted through social media might shake the job of a high-level FDA center director?
The FDA has to respect First Amendment limitations regulating scientific communication
Medtronic, as part of the settlement, will pay $602,000 to a whistleblower to settle charges it caused physicians to submit false claims to federal health programs.
More Articles by James G. Dickinson
- Veeva and QuintilesIMS tussle over customer reference data
- What five different pharma marketing careers look like
- Five things for pharma marketers to know: Monday, March 27, 2017
- Five things for pharma marketers to know: Friday, March 24, 2017
- Five things for pharma marketers to know: Tuesday, March 28, 2017
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media